Meredith S. Pelster

652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

Kathryn C. Arbour, Salman R. Punekar, Ignacio Garrido‐Laguna et al. · Annals of Oncology · 2023 · 102 citations · Full text

Tumor Biology, Medicine, Pharmacology +8

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with <i>KRAS</i> G12C-Mutated Metastatic Colorectal Cancer

Rona Yaeger, Nataliya V. Uboha, Meredith S. Pelster et al. · Cancer Discovery · 2024 · 88 citations · Full text

EDGE-Gastric Arm A1: Phase 2 study of domvanalimab, zimberelimab, and FOLFOX in first-line (1L) advanced gastroesophageal cancer.

Yelena Y. Janjigian, Do‐Youn Oh, Meredith S. Pelster et al. · Journal of Clinical Oncology · 2023 · 28 citations

Esophageal Cancer, Edge-gastric Arm A1, Immunology +18

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Ignacio Garrido‐Laguna, Brian M. Wolpin, Wungki Park et al. · Journal of Clinical Oncology · 2025 · 25 citations

Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial.

Milind Javle, Amit Mahipal, Lionel Aurelien Kankeu Fonkoua et al. · Journal of Clinical Oncology · 2024 · 13 citations